Alvotech Feed

	Est. tid*
2027-03-11	N/A	Bokslutskommuniké 2026
2026-11-12	22:40	Kvartalsrapport 2026-Q3
2026-08-20	22:40	Kvartalsrapport 2026-Q2
2026-05-07	22:40	Kvartalsrapport 2026-Q1
2026-03-19	N/A	Bokslutskommuniké 2025
2025-11-12	-	Kvartalsrapport 2025-Q3
2025-08-14	-	Kvartalsrapport 2025-Q2
2025-06-26	-	X-dag ordinarie utdelning ALVO 0.00 ISK
2025-06-25	-	Årsstämma
2025-05-08	-	Kvartalsrapport 2025-Q1
2025-03-26	-	Bokslutskommuniké 2024
2024-11-14	-	Kvartalsrapport 2024-Q3
2024-08-16	-	Kvartalsrapport 2024-Q2
2024-05-22	-	Kvartalsrapport 2024-Q1
2024-03-20	-	Bokslutskommuniké 2023
2023-11-14	-	Kvartalsrapport 2023-Q3
2023-08-17	-	Kvartalsrapport 2023-Q2
2023-06-06	-	Årsstämma
2023-05-19	-	Kvartalsrapport 2023-Q1

Land	Island
Lista	Large Cap Iceland
Sektor	Hälsovård
Industri	Medicinteknik

2026-01-07 23:00:00 Leiðrétting: Viðskipti stjórnenda og tengdra aðila

2026-01-07 23:00:00 Correction: Transactions of Managers and Closely Associated Persons

2026-01-06 21:00:00 Transactions of Managers and Closely Associated Persons

2026-01-06 21:00:00 Viðskipti stjórnenda og tengdra aðila

2026-01-06 21:00:00 Transactions of Managers and Closely Associated Persons

2026-01-06 21:00:00 Viðskipti stjórnenda og tengdra aðila

2026-01-06 13:15:00 Alvotech announces planned CEO succession and leadership transition

2026-01-06 13:15:00 Alvotech tilkynnir breytingar á yfirstjórn félagsins

2026-01-06 13:15:00 Alvotech announces planned CEO succession and leadership transition

2025-12-31 22:30:00 Alvotech tryggir 100 milljóna dollara fjármögnun

2025-12-31 22:30:00 Alvotech Secures Term Loan Facility of USD 100 Million

2025-12-29 20:40:55 Changes in company's own shares 632,00 ISK | +0,64% | 17,8 MISK

2025-12-29 20:40:55 Breyting á fjölda eigin hluta 632,00 ISK | +0,64% | 17,8 MISK

2025-12-22 21:26:00 Alvotechs Finansiella Kalendar för 2026 634,00 ISK | +2,26% | 7,26 MISK

2025-12-22 21:26:00 Fjárhagsdagatal Alvotech fyrir árið 2026 634,00 ISK | +2,26% | 7,26 MISK

2025-12-22 21:26:00 Alvotech’s Financial Calendar for 2026 634,00 ISK | +2,26% | 7,26 MISK

2025-12-22 08:00:00 Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma 620,00 ISK | +0,32% | 3,49 MISK

2025-12-22 08:00:00 Alvotech og Advanz Pharma hefja sölu í Evrópu á fyrstu hliðstæðunni við Simponi 620,00 ISK | +0,32% | 3,49 MISK

2025-12-22 08:00:00 Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma 620,00 ISK | +0,32% | 3,49 MISK

2025-12-19 09:30:00 Alvotech og Teva ná samningi um að sala AVT06 hliðstæðunnar við Eylea má hefjast í Bandaríkjunum á fjórða ársfjórðungi 2026 618,00 ISK | +1,98% | 10,6 MISK

2025-12-19 09:30:00 Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® 618,00 ISK | +1,98% | 10,6 MISK

2025-12-17 08:30:00 Mikil umframeftirspurn alþjóðlegra fjárfesta í útboði Alvotech á breytanlegra skuldabréfum að fjárhæð 108 milljónir dollara 648,00 ISK | -1,82% | 7 057 MISK

2025-12-17 08:30:00 Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering 648,00 ISK | -1,82% | 7 057 MISK

2025-12-16 17:48:34 Alvotech býður út breytanleg skuldabréf að fjárhæð 100 milljónir bandaríkjadala til að viðhalda fjárfestingu í lyfjaþróun, framleiðslu, markaðssetningu og styrkja lausafjárstöðu, staðfestir afkomuspá 2025 og birtir afkomuspá ársins 2026 648,00 ISK | -1,82% | 7 057 MISK

2025-12-16 17:48:34 Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance 648,00 ISK | -1,82% | 7 057 MISK

2025-11-24 11:30:00 Markaðsleyfi veitt á Evrópska efnahagssvæðinu fyrir AVT03, hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva 670,00 ISK | +2,76% | 89,7 MISK

2025-11-24 11:30:00 Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area 670,00 ISK | +2,76% | 89,7 MISK

2025-11-20 10:00:00 Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) 674,00 ISK | +2,12% | 33,9 MISK

2025-11-20 10:00:00 Alvotech og Advanz Pharma fá markaðsleyfi á Evrópska efnahagssvæðinu fyrir Gobivaz, fyrstu hliðstæðuna við Simponi 674,00 ISK | +2,12% | 33,9 MISK

2025-11-12 22:40:00 Alvotech kynnir uppgjör fyrstu níu mánaða ársins 2025 og helstu áfanga í rekstri félagsins 694,00 ISK | -3,07% | 33,6 MISK

2025-11-12 22:40:00 Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update 694,00 ISK | -3,07% | 33,6 MISK

2025-11-10 10:00:00 UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept) 712,00 ISK | +1,71% | 49,6 MISK

2025-11-10 10:00:00 Alvotech vinnur sigur í mikilvægu dómsmáli um framleiðslu og markaðssetningu AVT06 hliðstæðunnar við Eylea (aflibercept) 712,00 ISK | +1,71% | 49,6 MISK

2025-11-10 10:00:00 UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept) 712,00 ISK | +1,71% | 49,6 MISK

2025-11-06 15:07:23 Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA 660,00 ISK | +3,77% | 47,1 MISK

2025-11-06 15:00:00 Alvotech og Advanz Pharma fá markaðsleyfi í Bretlandi fyrir Gobivaz, hliðstæðu við Simponi (golimumab) 660,00 ISK | +3,77% | 47,1 MISK

2025-11-06 15:00:00 Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA 660,00 ISK | +3,77% | 47,1 MISK

2025-11-04 22:01:00 Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update 636,00 ISK | -0,62% | 23,4 MISK

2025-11-04 22:01:00 Alvotech kynnir afkomu fyrstu níu mánaða ársins og ræðir nýjustu áfanga í rekstri félagsins þann 13. nóvember nk. 636,00 ISK | -0,62% | 23,4 MISK

2025-11-02 23:12:42 Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 680,00 ISK | -28,42% | 147 MISK

2025-11-02 23:10:00 Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT05 í Bandaríkjunum 680,00 ISK | -28,42% | 147 MISK

2025-11-02 23:10:00 Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 680,00 ISK | -28,42% | 147 MISK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Alvotech

Kalender

Beskrivning

Intresserad av bolagets nyckeltal?

Vem äger bolaget?

Alvotech

Kalender

Beskrivning

Intresserad av bolagets nyckeltal?

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden